Citadel Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-25,600
| Closed | -$154K | – | 10585 |
|
|
2019
Q4 | $154K | Sell |
25,600
-4,200
| -14% | -$24.3K | ﹤0.01% | 8349 |
|
|
2019
Q3 | $107K | Buy |
29,800
+11,200
| +60% | +$43.2K | ﹤0.01% | 8460 |
|
|
2019
Q2 | $50K | Buy |
+18,600
| New | +$54.9K | ﹤0.01% | 8734 |
|
|
2019
Q1 | – | Sell |
-14,300
| Closed | -$23K | – | 10193 |
|
|
2018
Q4 | $23K | Sell |
14,300
-5,700
| -29% | -$16.1K | ﹤0.01% | 8698 |
|
|
2018
Q3 | $74K | Buy |
20,000
+2,100
| +12% | +$6.26K | ﹤0.01% | 8688 |
|
|
2018
Q2 | $51K | Buy |
+17,900
| New | +$61K | ﹤0.01% | 8441 |
|
|
2018
Q1 | – | Sell |
-60,100
| Closed | -$173K | – | 9055 |
|
|
2017
Q4 | $173K | Buy |
60,100
+1,100
| +2% | +$4K | ﹤0.01% | 7205 |
|
|
2017
Q3 | $265K | Sell |
59,000
-1,900
| -3% | -$8.44K | ﹤0.01% | 6261 |
|
|
2017
Q2 | $280K | Buy |
60,900
+3,400
| +6% | +$13.7K | ﹤0.01% | 6013 |
|
|
2017
Q1 | $242K | Sell |
57,500
-28,000
| -33% | -$116K | ﹤0.01% | 6211 |
|
|
2016
Q4 | $353K | Buy |
85,500
+49,600
| +138% | +$264K | ﹤0.01% | 5442 |
|
|
2016
Q3 | $291K | Buy |
35,900
+11,100
| +45% | +$94.4K | ﹤0.01% | 5711 |
|
|
2016
Q2 | $193K | Buy |
24,800
+14,000
| +130% | +$120K | ﹤0.01% | 5864 |
|
|
2016
Q1 | $83K | Sell |
10,800
-37,500
| -78% | -$275K | ﹤0.01% | 6100 |
|
|
2015
Q4 | $521K | Buy |
48,300
+2,700
| +6% | +$24.5K | ﹤0.01% | 4420 |
|
|
2015
Q3 | $315K | Sell |
45,600
-3,000
| -6% | -$24.4K | ﹤0.01% | 5488 |
|
|
2015
Q2 | $431K | Sell |
48,600
-14,400
| -23% | -$136K | ﹤0.01% | 5209 |
|
|
2015
Q1 | $621K | Sell |
63,000
-45,300
| -42% | -$566K | ﹤0.01% | 4600 |
|
|
2014
Q4 | $1.33M | Sell |
108,300
-29,700
| -22% | -$363K | ﹤0.01% | 3394 |
|
|
2014
Q3 | $1.38M | Buy |
138,000
+114,400
| +485% | +$1.06M | ﹤0.01% | 3297 |
|
|
2014
Q2 | $179K | Buy |
23,600
+12,900
| +121% | +$51.5K | ﹤0.01% | 5685 |
|
|
2014
Q1 | $35K | Sell |
10,700
-4,400
| -29% | -$15.4K | ﹤0.01% | 7001 |
|
|
2013
Q4 | $50K | Sell |
15,100
-5,600
| -27% | -$16.2K | ﹤0.01% | 6040 |
|
|
2013
Q3 | $63K | Sell |
20,700
-10,000
| -33% | -$68.5K | ﹤0.01% | 5656 |
|
|
2013
Q2 | $251K | Buy |
+30,700
| New | +$234K | ﹤0.01% | 4460 |
|
Citadel Advisors's ACHN Position: Q1 2020 in Review
Citadel Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 51,221 shares — an estimated $309K sold.
Citadel Advisors first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $15.4M in Q3 2018. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Citadel Advisors reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Citadel Advisors sold 51,221 Achillion Pharmaceuticals shares in Q1 2020, an estimated $309K.
- Citadel Advisors first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Citadel Advisors's Achillion Pharmaceuticals position peaked at $15.4M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.